Cargando…

A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life

OBJECTIVE: To study the use of drugs in patients suffering from psoriasis and their effect on quality of life (QOL). MATERIALS AND METHODS: This was a prospective, observational study carried out in newly diagnosed patient of psoriasis at Department of Pharmacology and Outpatient Department of Skin...

Descripción completa

Detalles Bibliográficos
Autores principales: Karamata, V. V., Gandhi, A. M., Patel, P. P., Sutaria, A., Desai, M. K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351244/
https://www.ncbi.nlm.nih.gov/pubmed/28458428
http://dx.doi.org/10.4103/ijp.IJP_166_16
_version_ 1782514740845608960
author Karamata, V. V.
Gandhi, A. M.
Patel, P. P.
Sutaria, A.
Desai, M. K.
author_facet Karamata, V. V.
Gandhi, A. M.
Patel, P. P.
Sutaria, A.
Desai, M. K.
author_sort Karamata, V. V.
collection PubMed
description OBJECTIVE: To study the use of drugs in patients suffering from psoriasis and their effect on quality of life (QOL). MATERIALS AND METHODS: This was a prospective, observational study carried out in newly diagnosed patient of psoriasis at Department of Pharmacology and Outpatient Department of Skin and Venereal diseases at tertiary care teaching hospital, and patients were divided into three groups: Group A: topical therapy alone, Group B: methotrexate with topical therapy, and Group C: cyclosporine with topical therapy. The efficacy of drug was measured using Psoriasis Area Severity Index (PASI). QOL was measured using Psoriasis Disability Index. Patients were followed up at 1 month and 6 months of treatment. Statistical analysis was done using analysis of variance (ANOVA) test. RESULTS: A total 126 patients were enrolled, out of which 114 patients completed the study. PASI score was reduced significantly (P < 0.001) in each treatment group and QOL score was significantly (P < 0.001) decrease in Group B and C as compared to baseline at the end of 6 months. A significant (P < 0.001) reduction in PASI score and QOL was observed in patients of Group B and C as compared to Group A. Correlation between efficacy and QOL was not significant in all three treatment groups. CONCLUSION: Combination therapy (topical + systemic) is more efficacious and associated with significant improvement of QOL as compared to topical therapy alone. Methotrexate and cyclosporine are equally efficacious in treating and improving the QOL in patients suffering from psoriasis.
format Online
Article
Text
id pubmed-5351244
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-53512442017-04-28 A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life Karamata, V. V. Gandhi, A. M. Patel, P. P. Sutaria, A. Desai, M. K. Indian J Pharmacol Research Article OBJECTIVE: To study the use of drugs in patients suffering from psoriasis and their effect on quality of life (QOL). MATERIALS AND METHODS: This was a prospective, observational study carried out in newly diagnosed patient of psoriasis at Department of Pharmacology and Outpatient Department of Skin and Venereal diseases at tertiary care teaching hospital, and patients were divided into three groups: Group A: topical therapy alone, Group B: methotrexate with topical therapy, and Group C: cyclosporine with topical therapy. The efficacy of drug was measured using Psoriasis Area Severity Index (PASI). QOL was measured using Psoriasis Disability Index. Patients were followed up at 1 month and 6 months of treatment. Statistical analysis was done using analysis of variance (ANOVA) test. RESULTS: A total 126 patients were enrolled, out of which 114 patients completed the study. PASI score was reduced significantly (P < 0.001) in each treatment group and QOL score was significantly (P < 0.001) decrease in Group B and C as compared to baseline at the end of 6 months. A significant (P < 0.001) reduction in PASI score and QOL was observed in patients of Group B and C as compared to Group A. Correlation between efficacy and QOL was not significant in all three treatment groups. CONCLUSION: Combination therapy (topical + systemic) is more efficacious and associated with significant improvement of QOL as compared to topical therapy alone. Methotrexate and cyclosporine are equally efficacious in treating and improving the QOL in patients suffering from psoriasis. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5351244/ /pubmed/28458428 http://dx.doi.org/10.4103/ijp.IJP_166_16 Text en Copyright: © 2017 Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Research Article
Karamata, V. V.
Gandhi, A. M.
Patel, P. P.
Sutaria, A.
Desai, M. K.
A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life
title A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life
title_full A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life
title_fullStr A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life
title_full_unstemmed A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life
title_short A study of the use of drugs in patients suffering from psoriasis and their impact on quality of life
title_sort study of the use of drugs in patients suffering from psoriasis and their impact on quality of life
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351244/
https://www.ncbi.nlm.nih.gov/pubmed/28458428
http://dx.doi.org/10.4103/ijp.IJP_166_16
work_keys_str_mv AT karamatavv astudyoftheuseofdrugsinpatientssufferingfrompsoriasisandtheirimpactonqualityoflife
AT gandhiam astudyoftheuseofdrugsinpatientssufferingfrompsoriasisandtheirimpactonqualityoflife
AT patelpp astudyoftheuseofdrugsinpatientssufferingfrompsoriasisandtheirimpactonqualityoflife
AT sutariaa astudyoftheuseofdrugsinpatientssufferingfrompsoriasisandtheirimpactonqualityoflife
AT desaimk astudyoftheuseofdrugsinpatientssufferingfrompsoriasisandtheirimpactonqualityoflife
AT karamatavv studyoftheuseofdrugsinpatientssufferingfrompsoriasisandtheirimpactonqualityoflife
AT gandhiam studyoftheuseofdrugsinpatientssufferingfrompsoriasisandtheirimpactonqualityoflife
AT patelpp studyoftheuseofdrugsinpatientssufferingfrompsoriasisandtheirimpactonqualityoflife
AT sutariaa studyoftheuseofdrugsinpatientssufferingfrompsoriasisandtheirimpactonqualityoflife
AT desaimk studyoftheuseofdrugsinpatientssufferingfrompsoriasisandtheirimpactonqualityoflife